NEOG vs NTLA
Neogen Corp. and Intellia Therapeutics, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | NEOG | NTLA |
|---|---|---|
| Revenue | $870.4M | $67.7M |
| Net income | $-7.9M | $-412.7M |
| Gross margin | 46.9% | · |
| Net margin | −0.9% | −609.9% |
| Return on equity | −0.4% | −53.5% |
| Diluted EPS | −$0.04 | −$3.81 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $31.9M | $-395.9M |
| Equity | $2.1B | $671.4M |
| Net debt / equity | 0.29× | · |
| Current ratio | 3.82× | 5.08× |
| Revenue CAGR 5y | 13.2% | 3.1% |
| Profit CAGR 5y | · | · |
NEOG bills 12.9× the revenue of NTLA, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | NEOG | NTLA |
|---|---|---|
| FY2025 | $870.4M | $67.7M |
| FY2024 | $894.7M | $57.9M |
| FY2023 | $924.2M | $36.3M |
| FY2022 | $822.4M | $52.1M |
| FY2021 | $527.2M | $33.1M |
| FY2020 | $468.5M | $58.0M |
| FY2019 | $418.2M | $43.1M |
| FY2018 | $414.2M | $30.4M |
| FY2017 | $397.9M | $26.1M |
| FY2016 | $358.3M | $16.5M |
Bottom line
| Fiscal year | NEOG | NTLA |
|---|---|---|
| FY2025 | $-7.9M | $-412.7M |
| FY2024 | $-1.1B | $-519.0M |
| FY2023 | $-9.4M | $-481.2M |
| FY2022 | $-22.9M | $-474.2M |
| FY2021 | $48.3M | $-267.9M |
| FY2020 | $60.9M | $-134.2M |
| FY2019 | $59.5M | $-474.2M |
| FY2018 | $60.2M | $-85.3M |
| FY2017 | $63.1M | $-67.5M |
| FY2016 | $43.8M | $-31.6M |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$802,729,000 | NEOG |
| FY2024 | +$836,823,000 | NEOG |
| FY2023 | +$887,925,000 | NEOG |
| FY2022 | +$770,326,000 | NEOG |
| FY2021 | +$494,106,000 | NEOG |
| FY2020 | +$410,465,000 | NEOG |
| FY2019 | +$375,067,000 | NEOG |
| FY2018 | +$383,752,000 | NEOG |
| FY2017 | +$371,813,000 | NEOG |
| FY2016 | +$341,798,000 | NEOG |
NEOG has reported the higher revenue in every one of these 10 fiscal years. The gap has widened since the earliest year compared.
10 of 17 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +608.9 pp | NEOG |
| FY2024 | +774.7 pp | NEOG |
| FY2023 | +1325.5 pp | NEOG |
| FY2022 | +907.0 pp | NEOG |
| FY2021 | +819.7 pp | NEOG |
| FY2020 | +244.5 pp | NEOG |
| FY2019 | +245.1 pp | NEOG |
| FY2018 | +294.9 pp | NEOG |
| FY2017 | +274.5 pp | NEOG |
| FY2016 | +204.2 pp | NEOG |
NEOG has kept the higher net margin in every one of these 10 fiscal years.
10 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NTLA's net margin has been more volatile than NEOG's over the 10 comparable fiscal years — 375.1 percentage points of standard deviation against 39.7.
10 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
NEOG led in net margin in every one of the 10 comparable fiscal years — a structural lead, not a recent swing.
10 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NTLA's return on equity has been more volatile than NEOG's over the 9 comparable fiscal years — 43.0 percentage points of standard deviation against 15.5.
9 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
NEOG led in return on equity in every one of the 9 comparable fiscal years — a structural lead, not a recent swing.
9 of 17 comparable fiscal years — a year missing data on either side is not counted.